Cargando…
Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open‐label, single‐arm, phase 3, and postmarketing clinical study
INTRODUCTION: Adenosine deaminase (ADA) deficiency is an ultrarare inherited purine metabolism disorder characterized by severe combined immunodeficiency. Elapegademase‐lvlr is a new pegylated recombinant bovine ADA used in enzyme‐replacement therapy (ERT) for ADA deficiency. Therefore, replacement...
Autores principales: | Onodera, Masafumi, Uchiyama, Toru, Ariga, Tadashi, Yamada, Masafumi, Miyamura, Takako, Arizono, Hironori, Morio, Tomohiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10367445/ https://www.ncbi.nlm.nih.gov/pubmed/37506145 http://dx.doi.org/10.1002/iid3.917 |
Ejemplares similares
-
Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy
por: Igarashi, Yuka, et al.
Publicado: (2017) -
Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer
por: Zhulai, Galina, et al.
Publicado: (2022) -
Adenosine deaminase activity in leukaemia.
por: Smyth, J. F., et al.
Publicado: (1975) -
Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones
por: Uchiyama, Toru, et al.
Publicado: (2021) -
Characteristics of pleural effusion with a high adenosine deaminase level: a case–control study
por: Shimoda, Masafumi, et al.
Publicado: (2022)